Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated:  5/3/2016
University of Colorado Hospital CRS
mi
from
Aurora, CO
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated: 5/3/2016
University of Colorado Hospital CRS
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated:  5/3/2016
Washington University Therapeutics (WT) CRS
mi
from
St. Louis, MO
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated: 5/3/2016
Washington University Therapeutics (WT) CRS
mi
from
St. Louis, MO
Click here to add this to my saved trials
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated:  5/3/2016
New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated: 5/3/2016
New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
Click here to add this to my saved trials
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated:  5/3/2016
Chapel Hill CRS
mi
from
Chapel Hill, NC
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated: 5/3/2016
Chapel Hill CRS
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated:  5/3/2016
Greensboro CRS
mi
from
Greensboro, NC
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated: 5/3/2016
Greensboro CRS
mi
from
Greensboro, NC
Click here to add this to my saved trials
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated:  5/3/2016
Cincinnati Clinical Research Site
mi
from
Cincinnati, OH
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated: 5/3/2016
Cincinnati Clinical Research Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated:  5/3/2016
Vanderbilt Therapeutics (VT) CRS
mi
from
Nashville, TN
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated: 5/3/2016
Vanderbilt Therapeutics (VT) CRS
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated:  5/3/2016
University of Washington AIDS CRS
mi
from
Seattle, WA
Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study
Status: Enrolling
Updated: 5/3/2016
University of Washington AIDS CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Status: Enrolling
Updated:  5/3/2016
Bridge HIV CRS
mi
from
San Francisco, CA
Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Status: Enrolling
Updated: 5/3/2016
Bridge HIV CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
RCT of CBT for Insomnia With PLWHA
A Randomized Controlled Trial of Cognitive Behavior Therapy for Insomnia With Persons Living With HIV/AIDS
Status: Enrolling
Updated:  5/5/2016
Grady Memorial Hospital/Infectious Disease Program
mi
from
Atlanta, GA
RCT of CBT for Insomnia With PLWHA
A Randomized Controlled Trial of Cognitive Behavior Therapy for Insomnia With Persons Living With HIV/AIDS
Status: Enrolling
Updated: 5/5/2016
Grady Memorial Hospital/Infectious Disease Program
mi
from
Atlanta, GA
Click here to add this to my saved trials
Sexually Transmitted Infections Among African American Women Who Have Sex With Women
Prevalence Rates of Sexually Transmitted Infections and Sexual Risk Behaviors Among African American Women Who Have Sex With Women
Status: Enrolling
Updated:  5/10/2016
Crossroads Clinic
mi
from
Jackson, MS
Sexually Transmitted Infections Among African American Women Who Have Sex With Women
Prevalence Rates of Sexually Transmitted Infections and Sexual Risk Behaviors Among African American Women Who Have Sex With Women
Status: Enrolling
Updated: 5/10/2016
Crossroads Clinic
mi
from
Jackson, MS
Click here to add this to my saved trials
Lung HIV Disease in a Large Cohort-Pitt
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-Pitt
Status: Enrolling
Updated:  5/10/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Lung HIV Disease in a Large Cohort-Pitt
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-Pitt
Status: Enrolling
Updated: 5/10/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Lung HIV Disease in a Large Cohort-Pitt
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-Pitt
Status: Enrolling
Updated:  5/10/2016
UPMC Montefiore Hospital, CTRC MUH, Keystone Bldg.
mi
from
Pittsburgh, PA
Lung HIV Disease in a Large Cohort-Pitt
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-Pitt
Status: Enrolling
Updated: 5/10/2016
UPMC Montefiore Hospital, CTRC MUH, Keystone Bldg.
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Yoga Intervention for Substance Use and ART Adherence in Community Reentry
Yoga Intervention for Substance Use and Antiretroviral Therapy Adherence in Community
Status: Enrolling
Updated:  5/10/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Yoga Intervention for Substance Use and ART Adherence in Community Reentry
Yoga Intervention for Substance Use and Antiretroviral Therapy Adherence in Community
Status: Enrolling
Updated: 5/10/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Arizona Allergy Associates
mi
from
Chandler, AZ
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Arizona Allergy Associates
mi
from
Chandler, AZ
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Miller Children's Hospital
mi
from
Long Beach, CA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Miller Children's Hospital
mi
from
Long Beach, CA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
IMMUNOe International Research Centers
mi
from
Centennial, CO
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
IMMUNOe International Research Centers
mi
from
Centennial, CO
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Allergy Associates of the Palm Beaches, PA
mi
from
N Palm Beach, FL
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Allergy Associates of the Palm Beaches, PA
mi
from
N Palm Beach, FL
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Rush University Medical Center
mi
from
Chicago, IL
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Institute for Asthma and Allergy, P.C.
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Asthma and Allergy Center
mi
from
Toledo, OH
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Asthma and Allergy Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Dallas Allergy Immunology Research
mi
from
Dallas, TX
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Dallas Allergy Immunology Research
mi
from
Dallas, TX
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
University of Utah / Primary Children's Hospital
mi
from
Salt Lake City, UT
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
University of Utah / Primary Children's Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
O&O Alpan
mi
from
Fairfax, VA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
O&O Alpan
mi
from
Fairfax, VA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Bellingham Asthma, Allergy, & Immunology Clinic
mi
from
Bellingham, WA
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Bellingham Asthma, Allergy, & Immunology Clinic
mi
from
Bellingham, WA
Click here to add this to my saved trials
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated:  5/11/2016
Egyesitett Szent Istvan es Szent Laszlo Korhaz
mi
from
Budapest,
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Status: Enrolling
Updated: 5/11/2016
Egyesitett Szent Istvan es Szent Laszlo Korhaz
mi
from
Budapest,
Click here to add this to my saved trials
HOPE (Harnessing Online Peer Education): Using Online Social Networks for HIV Prevention and Testing
Using Online Social Networks for HIV Prevention and Testing
Status: Enrolling
Updated:  5/17/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
HOPE (Harnessing Online Peer Education): Using Online Social Networks for HIV Prevention and Testing
Using Online Social Networks for HIV Prevention and Testing
Status: Enrolling
Updated: 5/17/2016
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
HOPE (Harnessing Online Peer Education): Using Online Social Networks for HIV Prevention and Testing
Using Online Social Networks for HIV Prevention and Testing
Status: Enrolling
Updated:  5/17/2016
Epicentro Commun
mi
from
Lima,
HOPE (Harnessing Online Peer Education): Using Online Social Networks for HIV Prevention and Testing
Using Online Social Networks for HIV Prevention and Testing
Status: Enrolling
Updated: 5/17/2016
Epicentro Commun
mi
from
Lima,
Click here to add this to my saved trials
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
Sex and Disease Dependent Nucleoside Analog Toxicity
Status: Enrolling
Updated:  5/18/2016
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
Sex and Disease Dependent Nucleoside Analog Toxicity
Status: Enrolling
Updated: 5/18/2016
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
HIV Prevention for Youth With Severe Mental Illness
HIV Prevention for Youth With Severe Mental Illness
Status: Enrolling
Updated:  5/19/2016
Rhode Island Hospital
mi
from
Providence, RI
HIV Prevention for Youth With Severe Mental Illness
HIV Prevention for Youth With Severe Mental Illness
Status: Enrolling
Updated: 5/19/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV
ART Adherence: Enhanced Counseling and Observed Therapy
Status: Enrolling
Updated:  5/19/2016
Kansas University Medical Center ID Clinic
mi
from
Kansas City, KA
Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV
ART Adherence: Enhanced Counseling and Observed Therapy
Status: Enrolling
Updated: 5/19/2016
Kansas University Medical Center ID Clinic
mi
from
Kansas City, KA
Click here to add this to my saved trials
Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV
ART Adherence: Enhanced Counseling and Observed Therapy
Status: Enrolling
Updated:  5/19/2016
Truman Medical Center ID Clinic
mi
from
Kansas City, MO
Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV
ART Adherence: Enhanced Counseling and Observed Therapy
Status: Enrolling
Updated: 5/19/2016
Truman Medical Center ID Clinic
mi
from
Kansas City, MO
Click here to add this to my saved trials
Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV
ART Adherence: Enhanced Counseling and Observed Therapy
Status: Enrolling
Updated:  5/19/2016
Kansas City Free Health Clinic
mi
from
Kansas City, MO
Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV
ART Adherence: Enhanced Counseling and Observed Therapy
Status: Enrolling
Updated: 5/19/2016
Kansas City Free Health Clinic
mi
from
Kansas City, MO
Click here to add this to my saved trials
Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV
ART Adherence: Enhanced Counseling and Observed Therapy
Status: Enrolling
Updated:  5/19/2016
Kansas City Veterans Administration Medical Center
mi
from
Kansas City, MO
Effectiveness of Enhanced Counseling and Observed Therapy on Antiretroviral Adherence in People With HIV
ART Adherence: Enhanced Counseling and Observed Therapy
Status: Enrolling
Updated: 5/19/2016
Kansas City Veterans Administration Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Rifaximin for Chronic Immune Activation in People With HIV
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects
Status: Enrolling
Updated:  6/1/2016
Walter Reed National Medical Center
mi
from
Bethesda, MD
Rifaximin for Chronic Immune Activation in People With HIV
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects
Status: Enrolling
Updated: 6/1/2016
Walter Reed National Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Rifaximin for Chronic Immune Activation in People With HIV
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects
Status: Enrolling
Updated:  6/1/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Rifaximin for Chronic Immune Activation in People With HIV
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects
Status: Enrolling
Updated: 6/1/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Rifaximin for Chronic Immune Activation in People With HIV
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects
Status: Enrolling
Updated:  6/1/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Rifaximin for Chronic Immune Activation in People With HIV
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects
Status: Enrolling
Updated: 6/1/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care: The mPeer2Peer Study
Status: Enrolling
Updated:  6/1/2016
Johns Hopkins University
mi
from
Baltimore, MD
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care: The mPeer2Peer Study
Status: Enrolling
Updated: 6/1/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers
Effect of BMS-663068 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects
Status: Enrolling
Updated:  6/1/2016
Miami Research Associates
mi
from
Miami, FL
A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers
Effect of BMS-663068 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects
Status: Enrolling
Updated: 6/1/2016
Miami Research Associates
mi
from
Miami, FL
Click here to add this to my saved trials
A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers
Effect of BMS-663068 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects
Status: Enrolling
Updated:  6/1/2016
ICON Early Phase Services, LLC (formerly named Healthcare Discoveries, LLC)
mi
from
San Antonio, TX
A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers
Effect of BMS-663068 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects
Status: Enrolling
Updated: 6/1/2016
ICON Early Phase Services, LLC (formerly named Healthcare Discoveries, LLC)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States
Status: Enrolling
Updated:  6/1/2016
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
mi
from
Boston, MA
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States
Status: Enrolling
Updated: 6/1/2016
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States
Status: Enrolling
Updated:  6/1/2016
Fenway Health (FH) CRS
mi
from
Boston, MA
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States
Status: Enrolling
Updated: 6/1/2016
Fenway Health (FH) CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States
Status: Enrolling
Updated:  6/1/2016
Soweto HVTN CRS
mi
from
Johannesburg,
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2 Vaccine Boosted by SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Vaccinia Naive Adult Participants in South Africa and the United States
Status: Enrolling
Updated: 6/1/2016
Soweto HVTN CRS
mi
from
Johannesburg,
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States
Status: Enrolling
Updated:  6/1/2016
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
mi
from
Boston, MA
Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States
Status: Enrolling
Updated: 6/1/2016
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States
Status: Enrolling
Updated:  6/1/2016
Fenway Health (FH) CRS
mi
from
Boston, MA
Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States
Status: Enrolling
Updated: 6/1/2016
Fenway Health (FH) CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States
Status: Enrolling
Updated:  6/1/2016
Soweto HVTN CRS
mi
from
Johannesburg,
Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
A Phase 1 Placebo-Controlled Study Extension to HVTN 073 / SAAVI 102, to Evaluate the Safety and Immunogenicity of Novartis Sub C gp140 Vaccine With MF59 Adjuvant, as a Boost Following SAAVI DNA-C2 Vaccine and SAAVI MVA-C Vaccine, in HIV Uninfected Healthy Adult Participants in South Africa and the United States
Status: Enrolling
Updated: 6/1/2016
Soweto HVTN CRS
mi
from
Johannesburg,
Click here to add this to my saved trials
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
A Phase Ib, Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Viral Suppression, Pharmacokinetics and Immune Modulatory Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals
Status: Enrolling
Updated:  6/2/2016
Clinical Trials Unit. University of Pennsylvania
mi
from
Philadelphia, PA
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
A Phase Ib, Randomized, Placebo Controlled, Double Blind Study to Determine the Safety, Viral Suppression, Pharmacokinetics and Immune Modulatory Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals
Status: Enrolling
Updated: 6/2/2016
Clinical Trials Unit. University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials